Search
CYT006-AngQb
go.drugbank.com/drugs/DB05739InvestigationalCYT006-AngQb is a therapeutic vaccine in development for treatment of hypertension. … It is designed to instruct the patient’s immune system to produce an antibody response against angiotensin II, a small peptide that causes blood vessels to narrow and results in increased blood pressure
Cefamandole
go.drugbank.com/drugs/DB01326ApprovedWithdrawnIt is no longer marketed in the United States. … Cefamandole is also known as cephamandole. It is a parenterally administered broad-spectrum cephalosporin antibiotic. It is generally formulated as a formate ester, [cefamandole nafate].
Synonyms: (6R,7R)-7-(R)-Mandelamido-3-(((1-methyl-1H-tetrazol-5-yl)thio)methyl)-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-carboxylic acid, (6R,7R)-7-{[(2R)-2-hydroxy-2-phenylacetyl]amino}-3-{[(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidLyme disease vaccine (recombinant OspA)
go.drugbank.com/drugs/DB00045ApprovedWithdrawnLipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant. … Vaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli.
Carfentanil
go.drugbank.com/drugs/DB01535IllicitInvestigationalVet approvedCarfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen. … Carfentanil is intended for large-animal use only as its extreme potency makes it inappropriate for use in humans.
Bamlanivimab
go.drugbank.com/drugs/DB15718ApprovedInvestigational[L20979] Based on phase 2 clinical trial (BLAZE-1) interim results, bamlanivimab was granted Emergency Use Authorization (EUA) by the FDA on November 10, 2020. … Bamlanivimab (LY-CoV555, also known as LY3819253), is a synthetic monoclonal antibody (mAb) derived from one of the first blood samples in the United States from a patient who recovered from COVID-19.
Creatine
go.drugbank.com/drugs/DB00148ApprovedInvestigationalNutraceuticalAn amino acid derivative that occurs in vertebrate tissues and in urine. In muscle tissue, creatine generally occurs as phosphocreatine. Creatine is excreted as creatinine in the urine.
Synonyms: N-methyl-N-guanylglycine, N-carbamimidoyl-N-methylglycineRisankizumab
go.drugbank.com/drugs/DB14762ApprovedInvestigational[L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019.
Products: SKYRIZI SOLUTION FOR INJECTION IN PRE-FILLED PEN 150MG/ML, Skyrizi solution for injection in pre-filled pen 150MG/MLAlectinib
go.drugbank.com/drugs/DB11363ApprovedInvestigationalApproved under accelerated approval in 2015, alectinib is indicated for use in patients who have progressed on or were not tolerant of crizotinib, which is associated with the development of resistance … Inhibition of ALK prevents phosphorylation and subsequent downstream activation of STAT3 and AKT resulting in reduced tumour cell viability.
CZEN 002
go.drugbank.com/drugs/DB05479ExperimentalIt appears that CZEN-002 works on a receptor in yeast that has yet to be identified. … A second focus was on the sequence Lys-Pro-Val (11-13) that is known to be important for antimicrobial activity.
Pegunigalsidase alfa
go.drugbank.com/drugs/DB14992ApprovedInvestigational[A259347,A259352] In May 2023, the EMA granted marketing authorization to pegunigalsidase alfa in the European Union (EU) for the treatment of adult patients with Fabry disease. … [A259352,L46342] Unlike other forms of recombinant alpha-galactosidase A, such as [agalsidase alfa] and [agalsidase beta], pegunigalsidase alfa uses a plant cell-based protein expression system, leading